New Perspectives on Quality Advancement, Ecosystem Collaboration, and Capital Empowerment @ CSGCT Park Tour – Shenzhen Station

Guest

Dr. Zhang Xi, who graduated from the National University of Singapore, is currently the Co-founder and Chief Scientific Officer of Singapore-based Baiji Biotech.

Leveraging profound professional expertise, Dr. Zhang Xi has accumulated extensive experience in the research and development of immune cell-based oncology drugs and their clinical translation, successfully achieving over thirty scientific achievements and invention patents. Dr. Zhang Xi leads the R&D team in relentless exploration and innovation in the field of immune cell therapy, striving to provide optimal treatment solutions for cancer patients.

Wang Mingjun is the Executive Dean of the Shenzhen InnoTranslational Medicine Research Institute and the Executive Vice General Manager and CEO of Shenzhen InnoImmune Co., Ltd. He holds a Ph.D. in Immunology from the University of Copenhagen, Denmark, and completed his postdoctoral fellowship at Baylor College of Medicine in Houston, USA. His primary focus is on the research and development, translational application, and industrialization of tumor cell immunotherapy products. He has published more than 30 SCI-indexed academic papers and contributed three chapters to monographs. He has been honored with the Chinese Medical Association Young Scientist Award, the First Prize of the Guangdong Medical Science and Technology Award, the title of “Annual Emerging Entrepreneur” in the Individual Category of the “2018 Shenzhen Innovation List,” the National Outstanding Self-Funded Overseas Student Scholarship, recognition as an Overseas High-Level Talent under Shenzhen’s “Peacock Plan,” designation as an Outstanding Expert under Shenzhen Dapeng New District’s “Pengcheng Plan,” and the title of Shenzhen Excellent Communist Party Member. He is a member of the Society for Immunotherapy of Cancer (SITC), a deputy to the 7th Shenzhen Municipal People’s Congress, Vice President of the Shenzhen Western Returned Scholars Association, President of the Shenzhen Dapeng New District Association of Overseas Returnees, Council Member of the Shenzhen Overseas Exchange Association, Council Member of the Shenzhen Biomedical Promotion Association, and Vice President of the Shenzhen Life Sciences and Biotechnology Association.

Vice President of the Shenzhen Life Science Industry Association; Founder of Runde Biology. Graduated from Harbin Medical University with a degree in Clinical Medicine. Engaged in clinical medical practice after graduation, and subsequently held positions at Fortune 500 pharmaceutical companies such as BMS, Otsuka, and GSK. Has been active in the biopharmaceutical sector since 2012.

Dr. Yang Jiayin earned his degree from the Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, and has over 16 years of experience in the field of stem cells and regenerative medicine. He was previously recognized as an Overseas High-Level Talent in Shenzhen and currently serves as a Senior Engineer, a member of the Project Review Expert Pool of the Shenzhen Science and Technology Innovation Commission, an expert in the “High-Tech Expert Pool” of the Shenzhen Municipal Bureau of Industry and Information Technology, and Co-founder and Chief Technology Officer (CTO) of Sanqi Biotech. Since 2008, he has been engaged in research on iPSC reprogramming, genetic modification, disease modeling, and cell therapy, with a focus on developing universal, off-the-shelf iPSC-based cell therapies. Currently, multiple pipelines for oncology and autoimmune diseases are under development.

Mr. Zheng graduated from Tianjin University in 1985 and was selected for the Ministry of Education’s state-sponsored master’s program abroad. He completed his Master of Engineering and partial doctoral studies at the University of Toronto, and earned an MBA from the Ivey Business School in Canada. In 1994, he joined McKinsey & Company. Subsequently, he served as Vice President for China at Johnson & Johnson (J&J), Tianjin Sino-American SmithKline Pharmaceuticals, GlaxoSmithKline (GSK), and Jiangzhong Pharmaceutical Group, holding these positions until 2000. Since 2001, he has invested in nearly 100 healthcare companies, including industry leaders such as Shandong Weigao, Grand Pharma, Angelalign, and uLab.

In 2018, upon returning to China, he collaborated with nephrology scientists from Harvard University, Kyoto University, and Sun Yat-sen University to establish Shenzhen Huayuan Regenerative Medicine, a company dedicated to renal cell therapy and the development of bioartificial kidneys, as well as Huajin Nephrology Research and Drug Screening, a firm leveraging kidney organoids, organs-on-chips, and mimetics for kidney disease research and drug screening. He also co-founded Kangwo Bio-manufacturing with professors from Wuhan University and Zhejiang University, utilizing human-derived stem cells and biomaterials through acoustic assembly and 3D printing to fabricate high-performance human tissues and organs, including nerve bundles, cerebral cortex, cell-laden cartilage, liver, and pancreas. Furthermore, he jointly established Hong Kong Yuanbo AI Biomedical Devices with scientists from Harvard University, City University of Hong Kong, and The Chinese University of Hong Kong, pioneering the world’s first microencapsulation biological analysis platform, which has received support from multiple Hong Kong government funds, among other ventures such as Huachun Biological Nanomembrane Co., Ltd.

Xiaoyu Liang, a molecular and cellular biologist, specializes in genomics, gene editing, and RNA biology. She earned her Ph.D. from Southern Methodist University in the United States. After graduation, she worked as a scientist at Tome Biosciences, a biotechnology company based in Boston, USA. She currently serves as the Chief Technology Officer (CTO) of Shenzhen iDNA Biotechnology Co., Ltd. Dr. Liang has extensive experience in site-specific insertion of large DNA fragments, integrase development, and preclinical studies on the off-target and on-target effects of CRISPR/Cas9. She has successfully led interdisciplinary collaborative projects, applying gene editing to address complex challenges in liver diseases and cardiovascular disorders. She participated in and spearheaded the research, development, and optimization of key technologies during the Investigational New Drug (IND) application process, achieving the first proof-of-concept for functional site-specific integration of large DNA fragments at an efficiency exceeding 10% in non-human primates.

Dr. Pang Yuxuan, Assistant to the President of the Shenzhen Medical Academy of Research and Translation, is responsible for corporate collaboration and the commercialization of scientific and technological achievements. With eight years of investment experience in the biopharmaceutical sector, he focuses on innovative drugs, biotechnology, research services, and innovative medical devices.

Responsible for the overall operational management and business development of the Bay Area Gravity Experimental Platform.

With over 10 years of experience in managing biopharmaceutical R&D and production laboratories, I have held mid-to-senior management positions at several leading companies. I have led teams to establish process development, delivery systems, and quality systems, and spearheaded the standardization of manufacturing processes for multiple CGT projects as well as related safety evaluation studies.

Former Head of Marketing, Greater China, Danaher Life Sciences Group; previously held positions including Asia Pacific Marketing Director, Greater China Marketing Director, Consumables Sales Manager, Business Development Manager, and Product Manager at companies such as Cytiva, GE Healthcare, PerkinElmer, and Thermo Fisher Scientific.

Ph.D. in Strategy, University of Montpellier (France); EMBA, Nankai University; M.Sc. in Biology, University of Manchester; Postgraduate Studies in Finance, The University of Hong Kong; currently pursuing an M.A. in Psychology at Arizona State University (USA). Industry Professor at UCMT; Honorary Director of GDA. Senior Engineer in Measurement, Testing, and Instrumentation across China. Thesis Advisor for Ph.D. in Health Management, DBA, and MBA programs at the University of Montpellier (France); Distinguished Lecturer for workshops at the Business School of The University of Hong Kong and Nankai University; Instructor for the Advanced Leadership Training Program in Biopharmaceuticals at Peking University Health Science Center; Guest Lecturer at Yihong Business School. Deputy Director of the MAH Special Committee under the Chinese Pharmaceutical Enterprise Management Association; Chief Researcher at the Life Sciences Enterprise Research Center of E-Drug Manager; Special Researcher at the China Biopharmaceutical Infrastructure Alliance. Planner/Host of the “ChatCGT” column.

Holds a Bachelor’s degree from Osaka University, Japan, and a Ph.D. in Biomedical Engineering from the National University of Singapore. Completed postdoctoral fellowships at the Agency for Science, Technology and Research (A*STAR) and the Singapore-MIT Alliance for Research and Technology (SMART), focusing on molecular biology, epidemiology, immunology, and virology. Possesses over ten years of R&D experience in organic chemistry and molecular biology, with in-depth knowledge of gene therapy regulatory requirements in China, the United States, Europe, Japan, South Korea, and Australia. Has supported clinical drug application projects across multiple global regions, providing comprehensive technical, manufacturing, and commercial support to advance VectorBuilder’s CDMO business in gene delivery vectors.

Plasmid Process Development Scientist, Shenzhen Yuanxing Gene Technology Co., Ltd.

Ph.D. from Peking University / Postdoctoral Fellow at Shenzhen Bay Laboratory, with extensive experience in gene editing, protein engineering, directed evolution, mutant library design, and RNA sequence design.

B.S. in Pharmacy from Peking University, Ph.D. in Chemistry from the Institute of Chemistry, Chinese Academy of Sciences, and M.Fin. from the University of International Business and Economics. Candidate for Think Tank Expert at CITIC Group & Healthcare Industry Expert at the Suzhou Branch; Director of the Healthcare Industry Group, Investment Banking Committee, CITIC Securities; licensed to practice in China, Hong Kong, and the United States; won two “New Fortune” Best Analyst awards in 2021 and received a “New Fortune” nomination in a specific category in 2022.

Dr. Zhang Yang joined CITIC Securities in 2014. He completed the RMB 1.18 billion financing for Shanghai Allist Pharmaceutical, the USD 110 million financing for OrbusNeich, and the IPO of Chengda Biotech—the first company spun off from a Chinese listed firm to list on the STAR Market (the first approved “A-share to A-share” spin-off). He also handled STAR Market IPOs for Yuekang Pharmaceutical, Yuandong Biology, Create Bioligic, Haichuang Pharma, Jinjiang Electronics, Aerospace Taixin, and Yingli Pharma; the Beijing Stock Exchange IPO for Kangleyiwei; Hong Kong stock IPOs for Chengda Biotech, Hepu Medicine, CARsgen Therapeutics, Imeik, Bio-Thera Solutions, and Juno Therapeutics; and the NASDAQ IPO for Corbus Pharmaceuticals. He served as joint lead underwriter for Frontier Biotechnologies and 3SBio, and handled refinancing for Kapu Biotech (the first case under the registration-based system) and Tofflon Science & Technology. Additionally, he advised on China Resources Pharmaceutical’s acquisition of Boya Bio-pharmaceutical, as well as financing deals for China Resources Bio-pharmaceutical and Lixin Pharmaceutical. He provided financial advisory services for CARsgen Therapeutics, Xingfu Chemical, Chengyi Pharmaceutical, Cyagen Biosciences, and Shenda Endoscopy. The total cumulative financing amount exceeded RMB 23.2 billion.

Inventor of the ZCBI (Zhongguancun Life Science Park CITIC Securities Bioeconomy IPO Index).

Mr. Fu Chao, Assistant to the General Manager and Vice President of Investment at Yanghe Investment. He holds a Master’s degree in Biology from Tsinghua University, dual Bachelor’s degrees in Biotechnology and Finance from Wuhan University, and is a Certified Public Accountant (CPA). With over ten years of investment experience in the biopharmaceutical sector, his portfolio includes Jet Biofil, Kanglu Biotech, Mingkang Medical, Genepioneer Biotechnologies, LinkedCare, Nuoer Medical, Respibiologics, Junyuan Biotech, Dayuan Chenguang, Dingbang Biotech, Huateng Biotech, and Aidigene.

Agenda